ArticleDiabetes & metabolism journal2011
Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy.
Article in Diabetes & metabolism journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.Lipids in health and disease · 2020Trial
- The Function of PPARα in Cancer Drug Development: A Promising Target for Cancer Treatment.Current cancer drug targets · 2026Review
- Peroxisome Proliferator-Activated Receptor Alpha Stimulation Preserves Renal Tight Junction Components in a Rat Model of Early-Stage Diabetic Nephropathy.International journal of molecular sciences · 2024Article
- Ethyl Acetate Fractions ofInternational journal of molecular sciences · 2024Article
- Oxidative stress, inflammation, and steatosis elucidate the complex dynamics of HgClScientific reports · 2024Article
- Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.Archives of pharmacal research · 2023Article
- The Proteome of Circulating Large Extracellular Vesicles in Diabetes and Hypertension.International journal of molecular sciences · 2023Article
- A comprehensive insight into the molecular and cellular mechanisms of the effects of Propolis on preserving renal function: a systematic review.Nutrition & metabolism · 2022Review
- Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor.Scientific reports · 2016Article
- Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan.Clinical science (London, England : 1979) · 2016Article
- Anthocyanin-rich Seoritae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice.Journal of translational medicine · 2015Article
- Diabetic kidney disease: from epidemiology to clinical perspectives.Diabetes & metabolism journal · 2014Review
- Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.Current hypertension reports · 2012Review
- Age-associated molecular changes in the kidney in aged mice.Oxidative medicine and cellular longevity · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARα) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Given that PPARα expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, blood pressure regulation, and the renin-angiotensin aldosterone system, PPARα likely influences the development and pathogenesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. These findings suggest that PPARα may become an important therapeutic target for treating diabetic renal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.